Natera is trading 21% up at $321.21 after reporting $752.8 million in second-quarter revenue, well above expectations, and narrowing its loss to $0.47 per share.
- Management raised 2026 revenue guidance to $2.85 billion–$2.91 billion, a $100 million midpoint increase.
- Record test volumes and 57.2% year-over-year oncology growth reinforced the bullish outlook.